+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Epstein Barr Virus Drug"

From
Epstein Barr virus (EBV) - Pipeline Insight, 2024 - Product Thumbnail Image

Epstein Barr virus (EBV) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
Epstein Barr virus (EBV) - Epidemiology Forecast to 2032 - Product Thumbnail Image

Epstein Barr virus (EBV) - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
  • 6 Results (Page 1 of 1)
Loading Indicator

The Epstein Barr Virus (EBV) is a virus that is part of the herpes family and is one of the most common human viruses. It is the cause of infectious mononucleosis, also known as “mono” or “the kissing disease”. EBV is also associated with certain types of cancer, such as Burkitt’s lymphoma and nasopharyngeal carcinoma. The EBV drug market is a subset of the infectious diseases drug market. It includes drugs used to treat EBV-related illnesses, such as mono, as well as drugs used to treat EBV-related cancers. These drugs are typically antiviral medications, such as acyclovir, and chemotherapy drugs. The EBV drug market is highly competitive, with many companies developing and marketing drugs to treat EBV-related illnesses and cancers. Some of the major players in the market include GlaxoSmithKline, Merck, Pfizer, and Bristol-Myers Squibb. Other companies in the market include AstraZeneca, Novartis, and Johnson & Johnson. Show Less Read more